论文部分内容阅读
目的 观察泛昔洛韦对HBV慢性感染抗病毒的治疗效果。方法 慢性乙型肝炎患者 89例 ,采用随机对照分组 ,和单用泛昔洛韦治疗组 32例 ,和单用α 干扰素 2 9例和单用拉米夫定 2 8例两个对照组 ,对比观察三组抗病毒治疗效果。结果 治疗组泛昔洛韦血清HBVDNA阴转率 4 0 .6 2 % (13 32 ) ,HBeAg阴转率 2 1.88% (7 32 ) ;对照组α 干扰素血清HBVDNA阴转率 37.93% (11 2 9) ,HBeAg阴转率4 1 38% (12 2 9) ;拉米夫定血清HBVDNA阴转率 6 7.90 % (19 2 8) ,HBeAg阴转率 2 1.4 3% (6 2 8)。治疗组HBVDNA阴转时间最短 1个月 ,最长 3个月 ,平均 1.3个月 ,无 1例出现严重不良反应。结论 泛昔洛韦治疗HBV慢性感染安全有效。
Objective To observe the therapeutic effect of famciclovir on chronic hepatitis B virus infection. Methods Eighty-nine patients with chronic hepatitis B were randomly divided into two groups: control group (n = 32), famciclovir alone group (n = 29) and single interferon alpha (n = 29) Group anti-viral treatment effect. Results In the treatment group, the negative conversion rate of HBVDNA in famciclovir serum was 40.62% (13 32) and the negative conversion rate of HBeAg was 2.88% (7 32) in the treatment group. The negative conversion rate of HBVDNA in the control group was 37.93% (11 2 9) The negative conversion rate of HBeAg was 41.4% (12/29). The negative conversion rate of HBVDNA in lamivudine group was 6 7.90% (19 2 8), and the negative conversion rate of HBeAg was 2 1.4 3% (6 2 8). The treatment group HBVDNA minimum transfer time of 1 month, up to 3 months, an average of 1.3 months, no case of serious adverse reactions. Conclusions Famciclovir is safe and effective in the treatment of chronic HBV infection.